Treatment group | No. of dogs on day 0 | Â | Days post-treatment |
---|
0 | 7 | 14 | 21 | 28–30 | 40–45 | 56–60 | 82–86 |
---|
Fluralaner1 | 18 | Geomean flea count3 | 26.9b,x | 0.1a,y | 0.3a,y | 0.1a,y | 0.0a,y | 0.1a,y | 0.0a,y | 0.0a,y |
Range | (5–131) | (0–1) | (0–3) | (0–2) | (0–0) | (0–2) | (0–0) | (0–0) |
% control4 | Â | 99.7 | 99.0 | 99.8 | 100 | 99.6 | 100 | 100 |
% (#) dogs with no fleas | 0.0a,x (0/18) | 88.9a,y (16/18) | 72.2a,y (13/18) | 94.4a,y (17/18) | 100a,y (18/18) | 88.9a,y (16/18) | 100a,y (18/18) | 100a,y (18/18) |
Sarolaner2 | 13 | Geomean flea count3 | 37.9a,x | 0.1a,y | 0.1a,y | 0.2a,y | 0.1a,y | 0.0a,y | 0.0a,y | 0.0a,y |
Range | (10–171) | (0–1) | (0–1) | (0–2) | (0–1) | (0–0) | (0–0) | (0–0) |
% control4 | Â | 99.7 | 99.8 | 99.4 | 99.9 | 100 | 100 | 100 |
% (#) dogs with no fleas | 0.0a,x (0/13) | 84.6a,y (11/13) | 91.7a,y (11/12) | 76.9a,y (10/13) | 92.3a,y (12/13) | 100a,y (13/13) | 100a,y (13/13) | 100a,y (12/12) |
- 1In the fluralaner group dogs were treated once orally on day 0 (Bravecto chew; Merck Animal Health, Madison, NJ, USA)
- 2In the sarolaner group dogs were treated on day 0 and once between days 28–30 and 56–60 (Simparica chew; Zoetis, Whippany, NJ, USA)
- 3Geometric mean numbers of fleas in area counts
- 4{(Day 0 geometric mean animal area flea counts – day x geometric mean animal area flea counts) / day 0 geometric mean animal area flea counts)} × 100
- a,bGeometric mean flea counts in a column with unlike letter superscripts are significantly different (day 0, P = 0.034; │t│ = 2.14 )
- x,yGeometric mean flea counts in a row with unlike letter superscripts are significantly different from day 0 (P < 0.001; │t│ ≥ 22.83)
- a,bPercent of flea- free dogs in a column with like letter superscripts are not significantly different (P > 0.284; Fisher’s exact test)
- x,yPercent of flea- free dogs in a row with unlike letter superscripts are significantly different from day 0 (P < 0.001; Fisher’s exact test)